Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the acf domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/cr0ph/staging.phastar.com/wp-includes/functions.php on line 6260
ISS Success Story: Legacy Studies to Results
Abstract blue dotted wave on a black background

Turning Legacy Complexity into Submission-Ready Confidence

1 minute read

Published: November 24th, 2025

Discover how Phastar converted 16 legacy studies into SDTM and delivered a robust Integrated Summary of Safety (ISS) for a Multiple Sclerosis Spasticity program. Despite inconsistent legacy data, outdated coding, and complex integration requirements, Phastar applied structured methodology, proactive issue resolution, and harmonized integration to deliver clean, compliant, submission-ready datasets.

Complete the form below to read the full case study

Related articles

Protecting Trial Integrity- Independent Interim Analysis and IDMC Support in a Phase II Breast Cancer Study

Protecting Trial Integrity- Independent Interim Analysis and IDMC Support in a Phase II Breast Cancer Study

October 29th, 2026 1 minute read

Interim analyses and safety reviews play a critical role in clinical trial oversight, providing decision-makers with ...

Transforming Uncertainty into Statistical Confidence: Simulation-Driven Design for a First-in-Human Reproductive Therapeutic 

Transforming Uncertainty into Statistical Confidence: Simulation-Driven Design for a First-in-Human Reproductive Therapeutic 

July 20th, 2026 1 minute read

Designing a first-in-human study is challenging. Designing one for a novel reproductive therapy with limited prior da...

Turning Complexity into Regulatory Confidence: Designing a Seamless Phase 2b/3 Strategy for FDA Engagement 

Turning Complexity into Regulatory Confidence: Designing a Seamless Phase 2b/3 Strategy for FDA Engagement 

July 20th, 2026 1 minute read

Accelerating clinical development requires more than speed, it demands a careful balance between innovation, scientif...